Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Immediate-release niacin (vitamin B3)

Niacin (Immediate-Release Nicotinic Acid) · also known as Niacin, Immediate-release niacin, Nicotinic Acid, Flush niacin

Immediate-release niacin is a confirmed NAD+ precursor in humans. At pharmacologic doses it can raise HDL-C, but it often causes skin flushing. The eNOS- and AMPK-related mechanisms have not been confirmed in humans.

Typical dose: Start at 50–100 mg, then increase as tolerated to 250–500 mg/day, taken right after a meal with warm water. This dose is far above the US National Institutes of Health (NIH) adult tolerable upper intake level for niacin from supplements (35 mg/day). Use it only for a clear indication, and monitor liver function, blood glucose and uric acid.
Absorption and forms: Immediate-release niacin is absorbed quickly from the gut. Flushing, warmth and itching often start 15–30 minutes after a dose and last about 30–45 minutes. Tolerance develops gradually with several consecutive days of use. Immediate-release niacin is not entirely free of liver toxicity, and the risk of raised liver enzymes is generally thought to be higher with extended-release forms. Both forms should be used under a doctor’s guidance.

Clinical uses and human evidence

High LDL cholesterol

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Knopp 1998 · Metabolism · RCT · n=223 — Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
  2. McKenney 1994 · JAMA · RCT · n=46 — A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

High triglycerides

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Knopp 1998 · Metabolism · RCT · n=223 — Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia

All-cause mortality risk

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Schandelmaier 2017 · Cochrane Database Syst Rev · Meta-analysis · n=39195 — Niacin for primary and secondary prevention of cardiovascular events
  2. Canner 1986 · J Am Coll Cardiol · RCT · n=8341 — Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

Heart attack, stroke and other cardiovascular events

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. D'Andrea 2019 · JAMA Netw Open · Meta-analysis · n=35760 — Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
  2. Schandelmaier 2017 · Cochrane Database Syst Rev · Meta-analysis · n=39195 — Niacin for primary and secondary prevention of cardiovascular events

Mechanisms of action

Replenishing the NAD+ pool via the salvage pathway

★★★★★Mechanism evidence: grade A

Niacin is converted via the Preiss–Handler pathway, catalyzed by NAPRT, into nicotinic acid mononucleotide, which is then used to synthesize NAD+. This is a known synthesis route in humans. Human studies have confirmed that niacin is a precursor of NAD+, but the size of the rise depends on dose, tissue and nutritional status.

References (1)
  1. Pirinen et al. 2020 · Small human intervention study: after niacin was raised to 750–1000 mg/day, NAD+ rose in blood and, in some patients, in muscle

Endothelial nitric oxide synthase (eNOS) coupling and NO vasodilation

★★★☆☆Mechanism evidence: grade CSecondary target

The skin flushing from niacin comes from prostaglandin release after GPR109A receptor activation, not from eNOS activation. Vascular effects linked to eNOS have been seen in specific animal models, such as diabetic ischemia, but they cannot be extrapolated to a vasodilating effect at usual doses in humans.

References (2)
  1. 2005 · Knockout mouse study: niacin flushing depends on the prostaglandin pathway, and loss of eNOS did not abolish flushing
  2. Huang et al. 2012 · Mouse study: an eNOS-related angiogenic effect was observed in a diabetic ischemia model

AMPK sensing of cellular energy deficit and metabolic reprogramming

★★☆☆☆Mechanism evidence: grade CSecondary target

Some studies suggest niacin reduces hepatic triglyceride synthesis and VLDL secretion, but this is not the same as AMPK activation. In the livers of mice on a high-fat diet, niacin can indirectly increase AMPK phosphorylation, but there is no direct evidence in humans.

References (1)
  1. 2020 · Mouse and cell study: niacin increased AMPK phosphorylation in the livers of high-fat-diet mice, involving GPR109A signaling

Safety and drug interactions

Contraindicated in active severe peptic ulcer disease, uncontrolled severe liver disease, or during an acute gout attack (niacin competes with uric acid for the renal tubular excretion route). Do not take it on an empty stomach or with hot water, to avoid intense flushing. Immediate-release niacin can also raise liver enzymes, so liver function should be checked regularly with long-term high-dose use. When it is combined with a statin, monitor for myopathy, especially at high doses. Niacin can raise blood glucose and uric acid, so people with diabetes or gout should be monitored.

Added liver burden

High doses, especially extended-release forms, are hepatotoxic. Each of these has case reports of liver injury. If several are taken together long term, have liver function checked regularly. Stop them right away and see a doctor if you develop fatigue, poor appetite, yellowing of the skin or whites of the eyes, or darker urine.

With Antidiabetic drugs Needs attention

Metformin, insulin, sulfonylureas such as glimepiride, DPP-4 inhibitors, SGLT2 inhibitors

High-dose niacin raises blood sugar and may weaken the effect of antidiabetic drugs.

With Statins Needs attention

Atorvastatin, simvastatin, rosuvastatin

Combining high-dose niacin with a statin increases the risk of muscle injury. Seek prompt medical attention for muscle aches or weakness. The U.S. prescribing information specifically states that, in Chinese patients taking simvastatin, combining it with more than 1 g/day of niacin is not recommended.

Related lab tests

Fasting glucose and hemoglobin A1c Recheck while taking

High-dose niacin raises blood glucose. People with diabetes or prediabetes should recheck blood glucose about 2 months after starting.

Lipid panel Recheck while taking

When niacin is used under medical supervision to adjust blood lipids, recheck the lipid panel to see the effect.

Uric acid Recheck while taking

Niacin raises uric acid and may trigger gout. Test once before starting, recheck during dose increases, and then about every 6 months.

Liver function tests Recheck while taking

Niacin may cause liver injury. Test once before starting, then recheck regularly during dose increases and afterward, roughly every 2 months.

Open in the interactive app ›